We were excited to present new data at the 2024 EORTC-NCI-AACR Symposium. A multi-omics approach using transcriptomic and spatial analysis to identify predictive immune biomarkers of response and toxicity following chemotherapy in head & neck cancers is by Anna Juncker-Jensen, Harry Nunns, Maryam Rohafza, Erinn Parnell, Qingyan Au, Lakshmi Chandramohan, and Kirsteen. H. Maclean.
NeoGenomics Laboratories
Hospitals and Health Care
Fort Myers, Florida 33,559 followers
One Lab. Vital Answers.
About us
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.
- Website
-
http://neogenomics.com
External link for NeoGenomics Laboratories
- Industry
- Hospitals and Health Care
- Company size
- 1,001-5,000 employees
- Headquarters
- Fort Myers, Florida
- Type
- Public Company
- Founded
- 2002
- Specialties
- Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
Locations
-
Primary
Get directions
9490 NeoGenomics Way
Fort Myers, Florida 33912, US
Employees at NeoGenomics Laboratories
Updates
-
There is a new actionable target for patients with advanced or metastatic gastric (GEJ) adenocarcinoma. 𝐂𝐥𝐚𝐮𝐝𝐢𝐧𝟏𝟖.𝟐 (CLDN18.2) is a new biomarker with a targeted therapy to treat gastric/GEJ cancer and can improve the outcome for patients. To learn how CLDN18.2 testing can enhance care and help your patients, we invite you to visit us online https://lnkd.in/gXXhYQfb or call us at 866.776.5907, option 3. #Gastric #Adenocarcinoma #Claudin182 . . . References 1: https://lnkd.in/e3AAGe3i 2: https://lnkd.in/gfyUPeFr 3: https://lnkd.in/gzhyHnZ2
-
We were excited to present new data at the 2024 EORTC-NCI-AACR Symposium. A multi-omics approach using transcriptomic and spatial analysis to identify predictive immune biomarkers of response and toxicity following chemotherapy in head & neck cancers is by Anna Juncker-Jensen, Harry Nunns, Maryam Rohafza, Erinn Parnell, Qingyan Au, Lakshmi Chandramohan, and Kirsteen. H. Maclean.
-
-
#NeoWearsPink is an annual tradition at #NeoGenomics! Team members wear pink on this special day during #BreastCancerAwarenessMonth to encourage scheduling a yearly #mammogram and to spread awareness about the power of #EarlyDetection. #LifeAtNeo #WorkAtNeo #NeoSPIRIT
-
-
-
-
-
+14
-
-
The CAP24 | The Pathologists’ Meeting is drawing to a close at the Wynn Las Vegas. Thank you to everyone who visited us – we enjoyed the chance to discuss how our solutions can meet your challenges of cancer care. Contact us to get started: https://lnkd.in/g24cu5_q #Pathology #CAP24 #CancerCare
-
-
𝐍𝐞𝐨𝐆𝐞𝐧𝐨𝐦𝐢𝐜𝐬 𝐑𝐞𝐜𝐞𝐢𝐯𝐞𝐬 𝐍𝐞𝐰 𝐘𝐨𝐫𝐤 𝐒𝐭𝐚𝐭𝐞 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥 𝐟𝐨𝐫 𝐍𝐞𝐨 𝐂𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞™ 𝐒𝐨𝐥𝐢𝐝 𝐓𝐮𝐦𝐨𝐫 𝐓𝐞𝐬𝐭 Today, #NeoGenomics announced that the New York State Department of Health has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE® DNA & RNA Lung, allowing for immediate commercial access in the state of New York. These next-generation sequencing (NGS) tests deliver better diagnostic value and cost-effectiveness than single gene testing and direct the first-line treatment of diverse solid tumors, including non-small cell lung cancer. Continue reading this press release online: https://lnkd.in/gmqbiJiA #oncology #cancertesting #solidtumor #NewYork
-
#NeoGenomics Laboratories is partnered with ImmunoGen, Inc. on a FOLR1 testing program to provide testing for folate receptor alpha (FRα), an actionable biomarker in ovarian cancer, to eligible patients. This testing program was designed to help reduce barriers to IHC testing for novel biomarkers and aid oncologists in making informed treatment decisions for their ovarian cancer patients. Testing for FRα expression is performed using the FDA-approved immunohistochemistry (IHC) companion diagnostic (CDx)—VENTANA FOLR1 (FOLR1-2.1) RxDx Assay. This CDx may indicate eligibility for treatment with the associated biomarker-driven therapy. To learn more about this program, the patient eligibility criteria, and to download the test requisition form, please visit: https://lnkd.in/g6p7Ags7 #OvarianCancer #CancerTesting #Oncology
-
CAP24 | The Pathologists’ Meeting is underway at the Wynn Las Vegas! Visit us at booth #219. • Learn about our new NGS profiles for #hematologic cancers and solid #tumors, and how our broad test menu allows you to develop personalized solutions and collaborative assessments. •We have a motto that working at Neo is where passion meets purpose, and colleagues from our #NeoGenomics talent acquisition team are on-site to discuss #career opportunities. #Pathology #CAP24 #LasVegas #CareerOpportunities #LifeAtNeo #WorkAtNeo
-
-
CAP24 | The Pathologists’ Meeting has kicked off at the Wynn Las Vegas. Visit us today and tomorrow at booth #219! • Learn about our new NGS profiles for hematologic cancers and solid tumors, and how our broad test menu allows you to develop personalized solutions and collaborative assessments. • Attendees, be sure to stop by #NeoGenomics at booth #219 as part of the CAP24’s Exhibit Hall Bingo! #Pathology #CAP24 #LasVegas
-
-
Visit us during CAP24 | The Pathologists’ Meeting at the Wynn Las Vegas. • Learn about our new NGS profiles for hematologic cancers and solid tumors, and how our broad test menu allows you to develop personalized solutions and collaborative assessments. • Attendees, be sure to stop by #NeoGenomics at booth #219 as part of the CAP24’s Exhibit Hall Bingo! #Pathology #CAP24 #LasVegas
-